Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Bing Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5496-2465; OpenAlex author ID A5101468867. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 3 papers · 2026: 5 papers

Papers 16

  1. Comparative Severe Complications After Laparoscopic Pancreatoduodenectomy in PDAC vs Non-PDAC Periampullary Cancer: A Retrospective Cohort Study. Co-author DOI 10.1002/jso.70286↗
  2. Spatiotemporal heterogeneity of recurrence and predictors after radical surgery for pancreatic ductal adenocarcinoma: a retrospective observational study. Co-author DOI 10.1007/s00464-026-13120-w↗
  3. Peritoneal cytology in pancreatic cancer: a comprehensive review on prognostic stratification and clinical decision-making. Co-author DOI 10.1007/s10555-026-10339-w↗
  4. Local Recurrence After Pancreatic Cancer Resection: A Multidisciplinary Review of Risk Factors and Potential Causes, Diagnostic Innovations, Emerging Therapeut… Co-author DOI 10.1007/s11864-026-01408-x↗
  5. Postoperative survival prediction in pancreatic ductal adenocarcinoma and adenosquamous carcinoma: development of the machine learning-based model. Co-author DOI 10.1097/js9.0000000000004008↗
  6. PLEK2 promotes migration and invasion in pancreatic ductal adenocarcinoma by MMP1 through IL-17 pathway. Co-author DOI 10.1007/s11010-024-05078-x↗
  7. Perioperative risk factors for overall survival of patients with pancreatic ductal adenocarcinoma underwent laparoscopic pancreaticoduodenectomy. Last author DOI 10.1007/s13304-025-02081-9↗
  8. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  9. Single-incision plus one port laparoscopic pancreaticoduodenectomy with major venous resection and reconstruction for pancreatic cancer (with video recordings). Last author DOI 10.1016/j.asjsur.2024.05.241↗
  10. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-024-57417-z↗
  11. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Co-author DOI 10.1177/10732748221141233↗
  12. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  13. Laparoscopic Pancreaticoduodenectomy with Superior Mesenteric Vein Resection and Artificial Vascular Graft Reconstruction for Borderline Resectable Pancreatic … Last author DOI 10.1007/s11605-020-04808-y↗
  14. The Effect of Age on Short- and Long-Term Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Laparoscopic Pancreaticoduodenectomy. Last author DOI 10.1097/mpa.0000000000001620↗
  15. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13929↗
  16. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Co-author DOI 10.1038/s41598-018-36214-5↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. He Cai · 6 shared papers, 2020–2026 · strength 1.40
  2. Zhong Wu · 4 shared papers, 2026 · strength 1.23
  3. Tianrui Kuang · 3 shared papers, 2026 · strength 0.84
  4. Xin Wang · 3 shared papers, 2024–2026 · strength 0.70
  5. Ke Cheng · 3 shared papers, 2022–2025 · strength 0.58
  6. Rui Wang · 2 shared papers, 2026 · strength 0.58
  7. Qiangxing Chen · 2 shared papers, 2024–2025 · strength 0.42
  8. Lingwei Meng · 3 shared papers, 2019–2020 · strength 0.40
  9. Rui Wang · 1 shared paper, 2026 · strength 0.33
  10. Jing Zhang · 1 shared paper, 2025 · strength 0.33
  11. Yuanhao Sun · 1 shared paper, 2026 · strength 0.32
  12. Zhong Wu · 1 shared paper, 2026 · strength 0.28
  13. Yu Cai · 1 shared paper, 2024 · strength 0.26
  14. Yunwei Sun · 1 shared paper, 2026 · strength 0.25
  15. Li Y · 1 shared paper, 2026 · strength 0.25
  16. Xu Wang · 1 shared paper, 2025 · strength 0.19
  17. Jin Xu · 1 shared paper, 2025 · strength 0.19
  18. He Cheng · 1 shared paper, 2025 · strength 0.19
  19. Weiding Wu · 1 shared paper, 2025 · strength 0.19
  20. Wenyan Xu · 1 shared paper, 2025 · strength 0.19
  21. Wei Wang · 1 shared paper, 2025 · strength 0.19
  22. Xianjun Yu · 1 shared paper, 2025 · strength 0.19
  23. Chenghao Shao · 1 shared paper, 2025 · strength 0.19
  24. Chen Liu · 1 shared paper, 2025 · strength 0.19
  25. Rong Liu · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.